Andarine

ID: andarine

Aliases: S-4, GTx-007

Type: compound

Route/form: oral preclinical/investigational SARM context

Status: research

Evidence level: preclinical

Best data tier: non-human experimental

Support scope: non-human/mechanistic

Source types: preclinical

Linked sources: 2

Broad outcomes: Fat loss / metabolic health, Muscle growth / performance / recovery, PEDs / AAS / thermogenics, Safety / regulatory

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• androgen receptor modulator
• arylpropionamide SARM

Optimization domains

• SARM
• bone
• body composition
• doping

Research basis

• Animal and PK work support S-4 as an orally bioavailable SARM with bone/body-composition signals.
• It is one of the older compounds commonly detected in SARM discussions and useful for showing how much of the category remains preclinical.
• The performance rationale is tissue-selective AR agonism, not controlled human enhancement evidence.

Limits, risks, and missing evidence

• No mature human efficacy or safety package for performance use was identified in this pass.
• Visual-side-effect anecdotes need better source separation from controlled data.
• SARM-class suppression, lipid/liver, androgen-sensitive tissue, product identity, and doping concerns remain unresolved.

Risk flags

• research compound
• preclinical only
• sarm class risk
• product identity risk
• doping

Linked papers, labels, and reviews

1. SARM treatment prevents bone loss and reduces body fat in ovariectomized rats
   preclinical / pubmed_andarine_ovx_rat_2006
   S-4/andarine animal model of bone and body-composition effects.
2. Pharmacokinetics of S-4, a non-steroidal selective androgen receptor modulator, in rats
   preclinical / pmc_andarine_pk_rat_2007
   Rat pharmacokinetic and oral bioavailability study for S-4/andarine.